James Rolke - 11 Feb 2025 Form 4 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Role
Chief Executive Officer, Director
Signature
/s/ J.P. Galda, as attorney-in-fact for James Rolke
Issuer symbol
REVB
Transactions as of
11 Feb 2025
Net transactions value
+$116,468
Form type
4
Filing time
13 Feb 2025, 18:07:18 UTC
Previous filing
28 Feb 2023
Next filing
31 Oct 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REVB Common Stock Award $116,468 +30,095 +71655% $3.87 30,137 11 Feb 2025 Direct F1
holding REVB Common Stock 42 11 Feb 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.